Current Report Filing (8-k)
June 05 2017 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June
3, 2017
MATINAS BIOPHARMA HOLDINGS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-38022
|
46-3011414
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
1545 Route 206 South, Suite 302
Bedminster, New Jersey
|
07921
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(908) 443-1860
Not Applicable
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 7.01
|
Regulation FD Disclosure.
|
On June 3, 2017,
Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release to report interim results from the Phase 2a
Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis, which is being
conducted by the National Institutes of Health. The press release is attached hereto as Exhibit 99.1.
The Company intends
to use the presentation included as Exhibit 99.2 to this report in connection with its investor conference call on June 5, 2017.
In accordance
with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits
99.1 and 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth
by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
|
Exhibit No.
|
|
Description.
|
|
|
99.1
|
|
Press Release, dated June 3, 2017.
|
|
|
99.2
|
|
Presentation, dated June 5, 2017.
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MATINAS BIOPHARMA HOLDINGS, INC.
|
|
|
|
Dated: June 5, 2017
|
By:
|
/s/ Roelof Rongen
|
|
|
Name: Roelof Rongen
|
|
|
Title: Chief Executive Officer
|
|
|
|
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2023 to Apr 2024